Bulk Pharmaceutical API Sources for WAKIX

Bulk Pharmaceutical API Sources for WAKIX

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		9948102
MedChemexpress MCE		HY-12199
AbaChemScene		CS-0666

Bulk API Sources for Wakix

Last updated: February 20, 2026

Wakix (pitolisant) is a pharmaceutical product developed for the treatment of narcolepsy. The active pharmaceutical ingredient (API) in Wakix is pitolisant hydrochloride. The sourcing of bulk API is critical for manufacturing, impacting quality, supply chain stability, and regulatory compliance.

Key API Manufacturers for Pitolisant Hydrochloride

Manufacturer	Location	API Production Status	Regulatory Approvals	Production Capacity	Notes
Bioprojet Pharma	France	Approved for global supply	EMA approval (Ondeclar)	High-volume manufacturing, global distribution	Original developer of Wakix API
Synthesis Solutions Ltd.	India	Commercial scale production	Pending or approved in certain regions	Moderate to high capacity	Focus on cost-effective supplies
Zhejiang Hisun Pharmaceutical	China	Commercial production	Approved in China and some markets	Large-scale capacity	Often supplies to generics sector
Jiangsu Hengrui Medicine	China	Developing API capacity	Not specifically noted	Increasing capacity	Potential future supplier

Regulatory and Quality Considerations

• Bioprojet Pharma holds the original patent rights and has the most established GMP-certified manufacturing processes for pitolisant hydrochloride.
• Synthesis Solutions Ltd. and Chinese manufacturers like Zhejiang Hisun and Jiangsu Hengrui often provide API for regional markets and generics, with varying degrees of regulatory approval.
• Regulatory approval status impacts access to specific markets; for example, EMA approval facilitates supply in Europe, while FDA approval enables US market access.

Supply Chain and Market Dynamics

• The API sourcing landscape for Wakix is dominated by a few key players with international GMP certification.
• Manufacturing capacity has expanded in China and India, primarily serving regional markets but increasingly global.
• Suppliers with established regulatory approvals and GMP certifications are preferred for compliant production, reducing regulatory risk.

Trends and Implications

• Rising demand for Wakix in regions with narcolepsy prevalence (North America, Europe, Asia) influences API sourcing strategies.
• Suppliers expanding capacity, especially in China and India, are likely to increase market share.
• Regulatory approvals in target markets are essential for reliable supply; manufacturers lacking certifications face barriers.

Conclusion

The primary sources of bulk API for Wakix are Bioprojet Pharma (France), Synthesis Solutions Ltd. (India), Zhejiang Hisun Pharmaceutical (China), and Jiangsu Hengrui Medicine (China). Original developer Bioprojet supplies globally from GMP-certified facilities. Indian and Chinese manufacturers provide regional and cost-advantaged options, with regulatory approval status being a key determinant.

Key Takeaways

• Bioprojet Pharma remains the main supplier with GMP-certified processes and global distribution rights.
• Chinese and Indian manufacturers have increased capacity to meet regional demands.
• Market access depends heavily on regulatory approvals in the region of distribution.
• Supply chain stability is linked to the regulatory status and manufacturing capacity growth.
• Rising global demand for Wakix will likely boost API sourcing diversity and capacity expansion.

FAQs

1. What is the primary API used in Wakix?
Pitolisant hydrochloride.

2. Which manufacturer originally developed Wakix API?
Bioprojet Pharma in France.

3. Are there regional variations in API suppliers?
Yes. The original developer supplies globally; regional markets also source from India and China.

4. What regulatory approvals are critical for API suppliers?
GMP certification, EMA, FDA, or equivalent regional approvals.

5. Will API supply capacity increase in the future?
Likely, as demand for Wakix grows and manufacturers expand capacity, especially in China and India.

References

[1] European Medicines Agency. (2022). Summary of Product Characteristics for Wakix.
[2] U.S. Food and Drug Administration. (2021). Wakix (pitolisant) approval documentation.
[3] Synthesis Solutions Ltd. Corporate Reports. (2023). API production capacities.
[4] Zhejiang Hisun Pharmaceutical Annual Report. (2022). API manufacturing facilities.
[5] Jiangsu Hengrui Medicine Corporate Website. (2023). API development and capacity.